Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Hopp Children's Tumor Center at NCT Heidelberg ready to start

The Dietmar Hopp Foundation donates 20 million Euro

No. 47b | 23/11/2016

Heidelberg University Hospital and the German Cancer Research Center (DKFZ) have founded the Hopp-Kindertumorzentrum at the NCT* Heidelberg, in short: KiTZ, a tumor center for therapy and research in pediatric oncology and hematology. Their aim is to create new diagnostic and therapeutic options to help children with cancer more effectively. The Dietmar Hopp Foundation will support the project with 20 million Euros towards the construction of the new center, as SAP founder and patron Dietmar Hopp announced at a press conference on November 23.

Prof. Dr. Andreas Kulozik, Prof. Dr. Olaf Witt, Dietmar Hopp, Annika, Prof. Dr. Michael Baumann, Prof. Dr. Stefan Pfister, Prof. Dr. Guido Adler (v.l.n.r.)
© Universitätsklinikum Heidelberg

The news that their two-year-old daughter was suffering from leukemia came as a terrible blow for Annika Obieglo's family. But today, four years later, the family can breathe a sigh of relief as Annika is considered to be cured. Thanks to intensive therapy, her leukemia was pushed back completely. Receiving a cancer diagnosis presents affected children and their relatives with an unimaginable burden.

"The battle against cancer is an important motivation of my foundation work. The idea that my sons might develop cancer has always been unbearable for me, especially when I was a young father. And although our family are not affected, I want to help families whose children have to cope with cancer," said Dietmar Hopp. "I am moved by the fact that I can help to set up this highly specialized center".

The construction of the children's tumor center will cost around 40 million Euros in total. In addition to the Dietmar Hopp Foundation, other sponsors have already promised their support to the "Hopp Children's Tumor Center at NCT Heidelberg", also called "KiTZ". "We are grateful to everyone who has made it possible that with this financial foundation, we are now able to enter the construction planning phase," says Professor Dr. Guido Adler, Chairman of the Board and Chief Medical Director of the University Hospital. "About a quarter of the costs for the construction of the children's center are still not covered. But we are confident that we will be able to find more supporters, and we should be able to start building in 2017."

Targetetd therapies for children with cancer

At the KiTZ, clinic and research will be working together under one roof and help children affected by cancer more quickly and in more targeted ways. Professor Dr. Michael Baumann, Chairman and Scientific Director at DKFZ, explains: "Doctors and scientists from the University Hospital and the DKFZ are already cooperating in order to take better care of our cancer patients. At the KiTZ, we will soon be able to translate our scientific findings in pediatric oncology, now receiving great attention worldwide, into more tailored diagnostic and treatment procedures."

The KiTZ's cornerstone is comprehensive medical care for young patients. "In the KiTZ, children and adolescents with oncological and hematological disorders will receive individual personalized outpatient, inpatient and day-care - from diagnostics to therapy and aftercare," explains Professor Dr. Andreas Kulozik, Medical Director of the Clinic for Pediatric Oncology, Hematology and Immunology at the Heidelberg University Hospital. Kulozik also emphasizes another aspect of the KiTZ: Looking after the young patients' natural desire for movement and leisure activities. "It's important that life is not brought to a standstill during cancer treatment - especially when a child needs to activate all his reserves to defeat this illness, together with the doctors," says Kulozik.

In addition to the physical condition, the patients' mental well-being also has priority at the KiTZ. Spaces for physical activities and music therapy for distraction and recovery in-house as well as outside have been created. "We are currently refining the concept to meet the holistic demands of children with cancer," summarizes Kulozik. He is a member of the Board of Directors of the KiTZ, along with Professor Dr. Stefan Pfister and Professor Dr. Olaf Witt. Witt is head of the section "Pediatric Brain Tumors and Individualized Pediatric Oncology" (ZIPO) at the Clinic for Pediatric Oncology, Hematology and Immunology as well as the Clinical Cooperation Unit "Pediatric Oncology" at the DKFZ. Pfister is Head of the Department "Pediatric Neurooncology" at the German Cancer Research Center (DKFZ) and Senior Physician at the Heidelberg University Hospital.

Clinical research for better diagnosis and treatment strategies

KiTZ's second important foothold is research. "In order to increase the healing potential of children with cancer, it is important to better understand the molecular causes of the disease in each individual patient and to derive from this understanding specific diagnostic and therapeutic procedures for the patient," says Witt. "At the KiTZ, we are able to drive innovative clinical trials even further so that new therapies can reach our patients more quickly." Even though nearly 80 percent of children with cancer are now treated successfully, the healing rates have been stagnating for many years. Cancer is still the second most common cause of death among children and adolescents under 18 years of age in Germany. "In pediatric oncology we are still missing medical concepts specifically tailored to young patients," explains Pfister. "To change this, we want to further extend pre-clinical research with about 20 research groups, looking for new keys for the diagnosis and treatment of these diseases." And he adds: "To help children with cancer, for whom there have been no suitable therapies so far, is the goal that drives us all."

* The NCT was founded in Heidelberg in 2004 as the first "Comprehensive Cancer Center" in Germany in cooperation with the German Cancer Research Center and Heidelberg University Hospital.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS